Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 3:37 AM
Ignite Modification Date: 2025-12-25 @ 3:37 AM
NCT ID: NCT05969002
Eligibility Criteria: * INCLUSION CRITERIA: * Diagnosis: Participants must have a B cell ALL (inclusive of CML with ALL transformation) * Age: 5-39 years * All participants \>=18 years old with relapsed/refractory B cell ALL potentially proceeding to CAR therapy at the NIH, or * Any participant \<18 potentially proceeding to CAR therapy at the NIH with a clinical indication for FDG PET-CT prior to CAR infusion: * History of prior EMD * History of post-HSCT relapse * Clinical signs or incidental findings suspicious for EMD * Peripheral disease out of proportion of bone marrow disease burden * Participants who are breastfeeding or plan to breastfeed must agree to discontinue/postpone breastfeeding within 24 hours of any PET-CT scan * Ability and willingness of participant or Legally Authorized Representative (LAR) to co-enroll on protocol 10-C-0086 "Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies". * Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: * Pregnant individuals are excluded from this study * History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study (e.g., FDG injection)
Healthy Volunteers: False
Sex: ALL
Minimum Age: 5 Years
Maximum Age: 39 Years
Study: NCT05969002
Study Brief:
Protocol Section: NCT05969002